Modulation of Human Cells by Virulent Francisella tularensis

有毒土拉弗朗西斯菌对人体细胞的调节

• 批准号: 10014174
• 负责人: Catharine Bosio
• 金额: $ 72.55万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10014174
• 关键词: Acellular Vaccines; Acute; Aerosols; Anti-inflammatory; Bacteria; Bacterial Infections; Carbohydrates; Cells; Cover-up; Dangerousness; Data; Defect; Dendritic Cells; Dengue Virus; Development; Disease; Francisella; Francisella tularensis; Goals; Health; Human; Immune response; Immune system; Immunosuppression; Immunosuppressive Agents; Impairment; In Vitro; Individual; Infection; Infectious Agent; Inflammation; Inflammatory; Inflammatory Response; Inhalation; Invaded; Laboratories; Legal patent; Lipid Synthesis Pathway; Lipids; Liposomes; Mediating; Membrane; Metabolic; Metabolic Pathway; Metabolism; Microbe; Mus; Natural Immunity; O Antigens; Pathogenicity; Play; Proteins; Pulmonary tularemia; Research; Role; Route; Secondary to; Sentinel; Signal Pathway; Signaling Molecule; Stimulus; Structure; Surface; Symptoms; Testing; Therapeutic; Time; Tularemia; USSR; United States; Virulence; Virulent; adaptive immunity; bioweapon; capsule; carbohydrate structure; cell killing; cytokine; in vivo; macrophage; mortality; mutant; novel; novel therapeutics; novel vaccines; off-patent; pathogen; pathogenic bacteria; prevent; programs; receptor; response; transmission process; vector-borne; weapons

Francisella tularensis (FT), the causative agent for tularemia, can infect humans by a number of routes, including vector-borne transmission. However, it is inhalation of the bacterium, and the resulting pneumonic tularemia, that represents the most dangerous form of disease. This is due to the short incubation time (3-5 days), non-specific symptoms, and a high mortality rate (greater than 80%) in untreated individuals. Furthermore, FT has been weaponized by both the United States and the former Soviet Union making it a viable candidate for use as a biological weapon. Despite over 80 years of research on FT around the world, very little is understood about the dynamic interaction of this bacterium with the host, especially following aerosol infection. My laboratory has established that, similarly to murine cells, human dendritic cells and macrophages are acutely susceptible to infection with FT, but fail to produce pro-inflammatory cytokines or undergo maturation. Further, virulent FT actively interferes with the ability of human DC and macrophages to respond to secondary stimuli. Understanding the mechanism by which FT actively suppresses DC and macrophage function is a central directive of my laboratory. We are tackling this directive in two different ways. Specific Aim 1: We are analyzing the role Francisella lipids play in mediating anti-inflammatory responses. Structures present on the surface of bacteria are the first components encountered by the host cell. Thus, it is possible that, in the context of FT infections, these structures contribute to the early, rapid suppression of human dendritic cells. Bacterial lipids represent one such structure. We have recently identified one of the active lipid species present in FT that inhibit inflammation. We have tested a synthetic version of this lipid and confirmed that it also impairs inflammatory responses. We have identified one of the receptors utilized by both the intact bacterium and purified lipid as well as a host signaling molecule required to promote immunosuppressive responses. Importantly, we have also demonstrated that FT lipids can limit pathogenic inflammatory responses driven by other infectious agents in vitro, including Dengue virus. We have screened FT lipids (including synthetic liposomes) for off target effects in vivo following delivery via multiple routes and have also found that they potently dampen inflammation driven by unrelated bacterial infection in vivo. We have filed a patent application for use of FT lipids as novel anti-inflammatory therapeutics. We are currently identifying the other lipids present in FT that contribute to suppression of inflammation and additional mechanisms by which they interfere with functions in human cell. We have generated a lipid mutant and identified a requirement for a specific species of FT lipid in evasion, but not suppression, of pro-inflammatory responses in human cells. Additionally, we are examining the contribution of host lipid synthesis pathways following infection with F. tularensis. Specific Aim 2: We are exploring the role of carbohydrates associated with the outer surface of FT in directing immunosuppressive programs in human cells. The major outer surface carbohydrate structure of FT is the O-Antigen (O-Ag) capsule. Typically, capsules are thought to simply cover up proteins present on the bacterial surface that could stimulate an inflammatory response. However, our data demonstrates that FT capsule directly inhibits pro-inflammatory responses in human cells. Further, we have demonstrated that capsule influences specific metabolic pathways in the host the modulate cell health and inflammatory responses. Utilizing mutants with specific defects in capsule synthesis along with purified FT capsule, we are currently identifying the specific receptors and host signaling pathways modulated by capsule to initiate an anti-inflammatory program in human cells.

图拉氏方济各氏菌(FT)是图拉热病的病原体，可通过多种途径感染人类，包括媒介传播。然而，吸入细菌和由此导致的肺炎图拉热症是最危险的疾病形式。这是由于未经治疗的患者的潜伏期短(3-5天)、非特异性症状以及高死亡率(大于80%)。此外，英国《金融时报》已经被美国和前苏联武器化，使其成为一个可行的生物武器候选者。尽管世界各地对FT的研究已有80多年的历史，但人们对这种细菌与宿主的动态相互作用知之甚少，尤其是在气溶胶感染之后。 我的实验室已经证实，与小鼠细胞类似，人类树突状细胞和巨噬细胞对FT感染非常敏感，但无法产生促炎细胞因子或经历成熟。此外，毒力FT能积极干扰人DC和巨噬细胞对二次刺激的反应能力。了解FT主动抑制DC和巨噬细胞功能的机制是我实验室的核心指导。我们正在以两种不同的方式处理这一指令。 具体目标1：我们正在分析弗朗西塞氏菌脂类在介导抗炎反应中所起的作用。细菌表面的结构是宿主细胞遇到的第一组分。因此，在FT感染的背景下，这些结构可能有助于早期、快速地抑制人类树突状细胞。细菌脂类就是这样一种结构。我们最近鉴定了FT中存在的一种抑制炎症的活性脂质物种。我们已经测试了这种脂质的合成版本，并证实它也会损害炎症反应。我们已经确定了完整的细菌和纯化的脂类都利用的受体之一，以及促进免疫抑制反应所需的宿主信号分子。重要的是，我们还证明了FT脂在体外可以限制由其他感染性物质驱动的致病性炎症反应，包括登革病毒。我们已经筛选了FT脂类(包括合成脂质体)通过多种途径递送后在体内的非靶向作用，并发现它们在体内有效地抑制由无关细菌感染引起的炎症。我们已经提交了一项将FT脂质用作新型抗炎疗法的专利申请。我们目前正在确定FT中存在的其他有助于抑制炎症的脂类，以及它们干扰人类细胞功能的其他机制。我们已经产生了一种脂质突变体，并确定了一种特定种类的FT脂质在逃避但不是抑制人类细胞中的促炎反应方面的需求。此外，我们正在研究感染图拉氏丝虫后宿主脂肪合成途径的贡献。 具体目标2：我们正在探索与FT外表面相关的碳水化合物在指导人类细胞免疫抑制程序中的作用。FT的主要外表面碳水化合物结构是O-抗原(O-Ag)胶囊。通常，胶囊被认为只是掩盖了细菌表面存在的蛋白质，这些蛋白质可能会刺激炎症反应。然而，我们的数据表明，FT胶囊直接抑制了人类细胞的促炎反应。此外，我们还证明了胶囊会影响宿主体内特定的代谢途径，从而调节细胞健康和炎症反应。利用胶囊合成中具有特定缺陷的突变体和纯化的FT胶囊，我们目前正在鉴定胶囊调控的特定受体和宿主信号通路，以启动人类细胞的抗炎计划。